• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis.阿普司特对银屑病关节炎患者CD39高表达调节性B细胞中信号转导及白细胞介素-10产生的影响。
Mediterr J Rheumatol. 2018 Mar 19;29(1):59-61. doi: 10.31138/mjr.29.1.59. eCollection 2018 Mar.
2
Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.阿普米司特可增加银屑病关节炎和银屑病患者中产生 IL-10 的调节性 B 细胞,并减少促炎 T 细胞和固有细胞。
Rheumatology (Oxford). 2019 Dec 1;58(12):2240-2250. doi: 10.1093/rheumatology/kez204.
3
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells.产生白细胞介素-10的调节性B细胞在银屑病关节炎和银屑病中功能受损,且与产生白细胞介素-17和干扰素γ的T细胞呈负相关。
Clin Immunol. 2017 Nov;184:33-41. doi: 10.1016/j.clim.2017.04.010. Epub 2017 Apr 28.
4
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.免疫介导疾病中的磷酸二酯酶4抑制剂:作用机制、临床应用、现状与未来展望
Curr Med Chem. 2017;24(28):3054-3067. doi: 10.2174/0929867324666170530093902.
5
The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.磷酸二酯酶4抑制剂阿普司特抑制Th1反应,但促进由6-磺酸乳糖胺(slan)树突状细胞诱导的Th17反应。
J Dermatol Sci. 2017 Aug;87(2):110-115. doi: 10.1016/j.jdermsci.2017.04.005. Epub 2017 Apr 20.
6
IL-12/IL-23p40 identified as a downstream target of apremilast in models of arthritis.在关节炎模型中,白细胞介素-12/白细胞介素-23 p40被确定为阿普司特的下游靶点。
Ther Adv Musculoskelet Dis. 2019 Feb 22;11:1759720X19828669. doi: 10.1177/1759720X19828669. eCollection 2019.
7
Th17 and Th22 cells in psoriatic arthritis and psoriasis.银屑病关节炎和银屑病中的 Th17 和 Th22 细胞。
Arthritis Res Ther. 2013 Sep 26;15(5):R136. doi: 10.1186/ar4317.
8
Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.磷酸二酯酶 4 抑制减轻银屑病样小鼠模型的皮肤炎症和白细胞介素-1β 的表达,但不抑制炎症小体激活。
Int J Mol Sci. 2021 Nov 28;22(23):12878. doi: 10.3390/ijms222312878.
9
Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.银屑病和银屑病关节炎是同一种疾病吗?IL-23/IL-17 轴数据。
Autoimmun Rev. 2017 Jan;16(1):10-15. doi: 10.1016/j.autrev.2016.09.015. Epub 2016 Sep 22.
10
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.银屑病和银屑病关节炎管理的新进展:聚焦阿普斯特
Drug Des Devel Ther. 2013;7:201-10. doi: 10.2147/DDDT.S32713. Epub 2013 Mar 27.

引用本文的文献

1
Regulatory B cells, the key regulator to induce immune tolerance in organ transplantation.调节性B细胞是诱导器官移植免疫耐受的关键调节因子。
Front Immunol. 2025 Apr 8;16:1561171. doi: 10.3389/fimmu.2025.1561171. eCollection 2025.
2
Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies.ROS 调控和经皮给药在抗银屑病纳米治疗中的进展。
J Nanobiotechnology. 2022 Oct 14;20(1):448. doi: 10.1186/s12951-022-01651-y.
3
Mediterranean Journal of Rheumatology March 2018 Highlights.《地中海风湿病学杂志》2018年3月刊亮点。
Mediterr J Rheumatol. 2018 Mar 19;29(1):11-12. doi: 10.31138/mjr.29.1.11. eCollection 2018 Mar.

本文引用的文献

1
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.免疫介导疾病中的磷酸二酯酶4抑制剂:作用机制、临床应用、现状与未来展望
Curr Med Chem. 2017;24(28):3054-3067. doi: 10.2174/0929867324666170530093902.
2
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells.产生白细胞介素-10的调节性B细胞在银屑病关节炎和银屑病中功能受损,且与产生白细胞介素-17和干扰素γ的T细胞呈负相关。
Clin Immunol. 2017 Nov;184:33-41. doi: 10.1016/j.clim.2017.04.010. Epub 2017 Apr 28.
3
Human regulatory B cells in health and disease: therapeutic potential.健康与疾病状态下的人类调节性B细胞:治疗潜力
J Clin Invest. 2017 Mar 1;127(3):772-779. doi: 10.1172/JCI85113.
4
Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.银屑病和银屑病关节炎是同一种疾病吗?IL-23/IL-17 轴数据。
Autoimmun Rev. 2017 Jan;16(1):10-15. doi: 10.1016/j.autrev.2016.09.015. Epub 2016 Sep 22.
5
Phenotypic and functional characteristics of CD39 human regulatory B cells (Breg).CD39人调节性B细胞(Breg)的表型和功能特征。
Oncoimmunology. 2016 Feb 26;5(2):e1082703. doi: 10.1080/2162402X.2015.1082703. eCollection 2016 Feb.
6
Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis.布雷格细胞在系统性硬化症患者中数量减少且功能受损。
Arthritis Rheumatol. 2016 Feb;68(2):494-504. doi: 10.1002/art.39437.
7
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.人 CD4+ CD39+ 调节性 T 细胞在共表达表面 CD73 或与 CD73+ 外泌体或 CD73+ 细胞接触时会产生腺苷。
Clin Exp Immunol. 2014 Aug;177(2):531-43. doi: 10.1111/cei.12354.
8
Adenosine production by human B cells and B cell-mediated suppression of activated T cells.人 B 细胞产生腺苷和 B 细胞介导的对活化 T 细胞的抑制作用。
Blood. 2013 Jul 4;122(1):9-18. doi: 10.1182/blood-2013-02-482406. Epub 2013 May 15.
9
IL-10-producing regulatory B cells (B10 cells) in autoimmune disease.自身免疫病中的 IL-10 产生调节性 B 细胞(B10 细胞)。
Arthritis Res Ther. 2013;15 Suppl 1(Suppl 1):S1. doi: 10.1186/ar3907. Epub 2013 Feb 11.
10
CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.CD19+CD24hiCD38hi B 细胞在维持调节性 T 细胞的同时限制 TH1 和 TH17 细胞的分化。
Sci Transl Med. 2013 Feb 20;5(173):173ra23. doi: 10.1126/scitranslmed.3005407.

阿普司特对银屑病关节炎患者CD39高表达调节性B细胞中信号转导及白细胞介素-10产生的影响。

The effect of Apremilast on signal transduction and IL-10 production in CD39high regulatory B cells in patients with psoriatic arthritis.

作者信息

Sakkas Lazaros I, Mavropoulos Athanasios, Zafiriou Efterpi, Roussaki-Schulze Aggeliki, Bogdanos Dimitrios P

机构信息

Department of Rheumatology and Clinical Immunology and.

Dermatology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.

出版信息

Mediterr J Rheumatol. 2018 Mar 19;29(1):59-61. doi: 10.31138/mjr.29.1.59. eCollection 2018 Mar.

DOI:10.31138/mjr.29.1.59
PMID:32185301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7045954/
Abstract

BACKGROUND

IL-10-producing regulatory B cells (Bregs) are of great importance in autoimmunity, as they inhibit proinflammatory T cells. We have shown that IL-10-producing Bregs in psoriatic arthritis(PsA) were decreased and inversely correlated with IFNγ+T cells (TH1 cells) and IL-17+ T cells (TH17 cells). B cells with overexpression of CD39 have also inhibitory effects on proinflammatory T cells.

PRELIMINARY RESULTS

Our preliminary data showed that Apremilast, a phosphodiesterase-4(PDE-4) inhibitor, used in the treatment of PsA and psoriasis (Ps) increased IL-10-producing Bregs and reduced IFNγ+CD3+ T cells and IL-17+CD3+ T cells. We also found reduced activation of p38MAP kinase and the transcription factor STAT3, two important signaling pathways of IL-10 production, in PsA.

SPECIFIC AIMS

The aim of this research proposal is to study for the first time the immunomodulatory effect of Apremilast on signaling pathways in peripheral blood mononuclear cells (PBMCs) and CD39high B cells in PsA and Ps.

METHODS

We will study CD39 expression in B cells from patients with PsA and Ps before and after Apremilast treatment and their relation to IFNγ+ and IL-17+ T cells. Activation of CREB (cAMP response element-binding protein), STAT3, and p38MAPK in PBMCs and CD39high B cells from patients with PsA and Ps before and after Apremilast. The effect of CD39high B cells on T cell IFNγ and IL-17 production will also be studied.

SIGNIFICANCE

This study will elucidate the molecular pathways of Apremilast and better define Bregs in PsA and Ps.

摘要

背景

产生白细胞介素-10的调节性B细胞(Bregs)在自身免疫中具有重要意义,因为它们可抑制促炎性T细胞。我们已经表明,银屑病关节炎(PsA)中产生白细胞介素-10的Bregs减少,且与干扰素γ+T细胞(TH1细胞)和白细胞介素-17+T细胞(TH17细胞)呈负相关。过表达CD39的B细胞对促炎性T细胞也有抑制作用。

初步结果

我们的初步数据显示,用于治疗PsA和银屑病(Ps)的磷酸二酯酶-4(PDE-4)抑制剂阿普司特可增加产生白细胞介素-10的Bregs,并减少干扰素γ+CD3+T细胞和白细胞介素-17+CD3+T细胞。我们还发现,PsA中p38丝裂原活化蛋白激酶和转录因子信号转导及转录激活因子3(STAT3)这两条白细胞介素-10产生的重要信号通路的激活减少。

具体目标

本研究计划的目的是首次研究阿普司特对PsA和Ps患者外周血单个核细胞(PBMCs)和CD39高表达B细胞信号通路的免疫调节作用。

方法

我们将研究PsA和Ps患者在阿普司特治疗前后B细胞中CD39的表达及其与干扰素γ+和白细胞介素-17+T细胞的关系。研究PsA和Ps患者在阿普司特治疗前后PBMCs和CD39高表达B细胞中cAMP反应元件结合蛋白(CREB)、STAT3和p38丝裂原活化蛋白激酶的激活情况。还将研究CD39高表达B细胞对T细胞干扰素γ和白细胞介素-17产生的影响。

意义

本研究将阐明阿普司特的分子途径,并更好地界定PsA和Ps中的Bregs。